The Journal of urology · 2008
A novel method of imaging calcium urolithiasis using fluorescence.
СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Figueiredo Jose Luiz, Passerotti Carlo C, Sponholtz Todd, Nguyen Hiep T, Weissleder Ralph
Аннотация
PURPOSE: In the surgical management of urolithiasis the goal of treatment is not only to remove calculi, but also prevent future stone formation by rendering the patient stone-free/fragment-free. Achieving this goal is often difficult with endoscopic procedures due to the inability to visualize small calculi well even with x-ray or ultrasound. We evaluated fluorescence probes as a novel method of identifying calculi in the urinary tract.
MATERIALS AND METHODS: In vitro calcium stones were incubated with each of the Osteosense 680 and Osteosense 750 calcium binding fluorescence probes, and imaged with a near infrared fluorescence imaging system. Using a mouse model calculi were placed in the renal pelvis and the probes were injected intravenously. Imaging was performed at various times after injection.
RESULTS: In vitro the Osteosense 680 probe demonstrated high binding affinity for calcium oxalate-struvite, calcium phosphate-struvite and ammonium urate-calcium oxalate-calcium phosphate stones, and lower binding affinity for the calcium phosphate stone. In contrast, the Osteosense 750 probe demonstrated high binding affinity for calcium oxalate-struvite and calcium phosphate-struvite stones, and lower binding affinity for calcium phosphate and ammonium urate-calcium oxalate-calcium phosphate stones. In vivo intravenous administration of the probes was successful in labeling all calcium stone types tested.
CONCLUSIONS: Fluorescence imaging provides a new method for identifying calculi in the urinary tract. The improved visualization of these stones/fragments would make endoscopic procedures less difficult, decrease the risk of complications and increase the chance of rendering the patient stone-free/fragment-free.
MATERIALS AND METHODS: In vitro calcium stones were incubated with each of the Osteosense 680 and Osteosense 750 calcium binding fluorescence probes, and imaged with a near infrared fluorescence imaging system. Using a mouse model calculi were placed in the renal pelvis and the probes were injected intravenously. Imaging was performed at various times after injection.
RESULTS: In vitro the Osteosense 680 probe demonstrated high binding affinity for calcium oxalate-struvite, calcium phosphate-struvite and ammonium urate-calcium oxalate-calcium phosphate stones, and lower binding affinity for the calcium phosphate stone. In contrast, the Osteosense 750 probe demonstrated high binding affinity for calcium oxalate-struvite and calcium phosphate-struvite stones, and lower binding affinity for calcium phosphate and ammonium urate-calcium oxalate-calcium phosphate stones. In vivo intravenous administration of the probes was successful in labeling all calcium stone types tested.
CONCLUSIONS: Fluorescence imaging provides a new method for identifying calculi in the urinary tract. The improved visualization of these stones/fragments would make endoscopic procedures less difficult, decrease the risk of complications and increase the chance of rendering the patient stone-free/fragment-free.